Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH). It is anticipated that this collaboration could also provide a platform for the...
Tempus, a leader in AI-enabled diagnostics, today unveiled a breakthrough technology for oncologists, Tempus ONE. This smart, voice-enabled, portable device brings Tempus’ proprietary platform and unparalleled library of multi-modal data to life, offering physicians real-time access to all the clinical insights and data contained in Tempus’ genomic reports...
Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced that Abdul Hamid Halabi has joined as Senior Vice President of Data Products. Abdul has been a pioneer in AI and healthcare, developing key concepts in AI-powered diagnostics and intelligent medical devices and will leverage his...
Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic testing and tailored treatment approaches for the oncology community. The collaboration will include an initiative to help facilitate patient identification for precision oncology by providing testing, via the Te...
Tempus, a leader in artificial intelligence and precision medicine, today announced an additional $200 million financing at a post-money valuation of $8.1 billion dollars, and an additional $250 million of convertible debt. The investors include Baillie Gifford, Franklin Templeton, Google, Novo Holdings, and funds and accounts managed by T. Rowe Price....
Tempus, a leader in artificial intelligence and precision medicine, today announced that it has CE marked its signature broad-panel genomic sequencing assay, xT. The CE marked xT test is now available for clinical use in Europe. As part of Tempus’ broader regulatory strategy, European clinicians and their patients...
Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that in collaboration with the American Society of Clinical Oncology (ASCO), the academic research community now has access to a dataset of 500 Glioblastoma patients with matched molecular and clinically data....
Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a strategic collaboration with Janssen Research & Development, LLC (Janssen), in which Tempus will work closely with Janssen data scientists and oncologists focused on oncology clinical development programs. The collaboration is part of a multi-year data...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, and LabCorp (NYSE: LH), a leading global life sciences company, today announced a collaboration with LabCorp’s drug development business, Covance. LabCorp will participate in Tempus's TIME Trial® Network and the companies...